Article Text

Download PDFPDF
Successful treatment of Verona integron-encoded metallo-β-lactamase-producing Klebsiella pneumoniae infection using the combination of ceftazidime/avibactam and aztreonam
  1. Ana Pelaez Bejarano1,
  2. Raquel Sánchez-del Moral1,
  3. Olalla Montero-Pérez1,
  4. Francisco Javier Martínez-Marcos2
  1. 1 Unidad de Gestión Clínica Farmacia Hospitalaria, Hospital Juan Ramon Jimenez, Huelva, Spain
  2. 2 Unidad de Gestión Clínica Enfermedades Infecciosas, Hospital Juan Ramon Jimenez, Huelva, Spain
  1. Correspondence to Dr Ana Pelaez Bejarano, Unidad de Gestión Clínica Farmacia Hospitalaria, Hospital Juan Ramon Jimenez, Huelva, Spain; pelaezana21l{at}gmail.com

Abstract

The case of a female who had an accident that caused an open fracture is reported. During hospitalisation, Verona integron-encoded metallo-β-lactamase (VIM)-producing Klebsiella pneumoniae was isolated. Antimicrobial susceptibility testing revealed resistance to β-lactam antibiotics, quinolones, trimethoprim/sulfamethoxazole, and susceptibility to tigecycline, colistin, fosfomycin and aminoglycosides. Synergistic activity of ceftazidime-avibactam and aztreonam was proved in vitro and a combined therapy with tigecycline was started. Combination with aminoglycosides was ruled out as it was not described in the literature and also in order to avoid side effects. Colistin was rejected because of its nephrotoxicity profile. The antibiotic treatment was assessed by a multidisciplinary team with a pharmacist who closely monitored adverse effects and interactions with other drugs. The total duration of this combination was 25 days, without any adverse events reported. Fourteen weeks after the accident the patient was discharged. After 2 months of follow-up neither relapses nor reinfections have been reported.

  • communicable diseases
  • case reports
  • drug monitoring
  • education
  • pharmacy
  • continuing
  • pharmaceutical preparations

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.